



Conference call 18 October 2018

MEDIVIR

Improving life for cancer patients
through transformative drugs

Uli Hacksell, PhD



Born: 1950, Member of the Board since 2018

Education: PhD from Uppsala University

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years' experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000–2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University

Other directorships: Chairman of the Boards of Cerecor Inc. and Adhera Therapeutics, and Member of the Boards of InDex Pharmaceuticals AB, Beactica AB and Uppsala University

Shares in Medivir: 4,000



Increased Focus on Clinical Development



- Clinical development critical for optimizing value
- Strong clinical portfolio
- Plan to make redundant approximately 60 positions, mainly within pre-clinical research and administration
- Reductions to reduce Medivir's annual running cost base by 2/3



For the early-stage Cutaneous T-cell Lymphoma

- FDA advise essential for phase III program design

Project, Mechanism	Indication	Clinical phase				Market
		Preclinical	Phase I	Phase II	Phase III	
Remetinostat Topical HDAC inhibitor	Early-stage cutaneous T-cell lymphoma and skin cancers					Potential Blockbuster



In collaboration with Stanford University School of Medicine, Medivir is providing remetinostat for the recent investigator-initiated phase II clinical study in patients with basal cell carcinoma

Birinapant







For the treatment of solid tumors

Announced positive safety data and signals of efficacy following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD's anti-PD-1 therapy, Keytruda[®] (pembrolizumab)

Project, Mechanism	Indication	Clinical phase				Market
		Preclinical	Phase I	Phase II	Phase III	
Birinapant SMAC mimetic	MSS colorectal cancer and other solid tumors (combo with Keytruda [®])					Blockbuster


For the treatment of liver cancers

Announced that the first patient has been enrolled and dosed with MIV-818 in a phase I/II study in patients with liver cancer

Project, Mechanism	Indication	Preclinical	Clinical phase			Market
			Phase I	Phase II	Phase III	
MIV-818, Nucleotide DNA polymerase inhibitor	Hepatocellular carcinoma and other liver cancers					Orphan US/EU; Large in Asia

For the treatment of osteoarthritis

- Announced positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa extension study (MIV-711-202)
- FDA draft guideline on structural endpoints and potential accelerated approval



“Medivir has a very strong clinical portfolio with inflection points in the near future that are crucial for optimizing its value. This calls for a firm management that is able to reinforce the focus on clinical development throughout the company.”

- Anna Malm Bernsten, Chairman of the Medivir Board

